MedPath

StatSeal vs Figure-of-Eight Suture for Vascular Closure in AF Ablation

Not Applicable
Recruiting
Conditions
Atrial Fibrillation (AF)
Vascular Access
Interventions
Device: Statseal
Device: Figure of eight suture
Registration Number
NCT06627959
Lead Sponsor
Mid and South Essex NHS Foundation Trust
Brief Summary

This study, titled aims to compare two vascular closure techniques after catheter ablation for atrial fibrillation (AF). Catheter ablation is a common procedure used to treat AF, but after the procedure, It is important to close the access site in the blood vessel to prevent bleeding. This study will evaluate whether the StatSeal device, a haemostatic disc, can help patients recover more quickly compared to the traditional figure-of-eight suture technique.

The primary objective of the study is to determine whether StatSeal reduces the time it takes for patients to start walking after the procedure (known as Time to Ambulation). Secondary objectives include comparing the time to complete haemostasis, discharge eligibility, incidence of adverse events, and patient comfort between the two techniques.

Participants in the study will be randomly assigned to receive either the StatSeal device or the figure-of-eight suture after their AF ablation procedure. The study will recruit 160 participants across multiple hospital sites, with 80 participants in each group. Both techniques are standard methods, and participants will be closely monitored for safety throughout the study.

By comparing these two closure techniques, the study aims to improve the recovery process for patients undergoing AF ablation and provide evidence on which method leads to better outcomes and patient experiences.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Male and female patients age >18
  • Elective catheter ablation for atrial fibrillation using a 6 to 14 Fr inner diameter introducer sheath with a minimum of 1 and maximum of 3 femoral venous access sites
  • Willing and able to give informed consent
Exclusion Criteria
  • Active systemic or cutaneous infection, or inflammation in vicinity of the groin
  • Platelet count < 100,000 cells/mm3
  • BMI > 45 kg/m2 or < 20 kg/m2
  • Attempted femoral arterial access or inadvertent arterial puncture
  • Procedural complications that interfered with routine recovery, ambulation, or discharge times
  • Incorrect sheath placement
  • Intraprocedural bleeding or thrombotic complications
  • Access site-specific eligibility criteria to exclude problems with gaining access or location of sheath
  • History of bleeding diathesis, coagulopathy, hypercoagulability, or thromboembolic events

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
StatsealStatsealThis group shall receive the StatSeal device for vascular closure
Figure of eight sutureFigure of eight sutureThis group shall receive the figure of eight suture (attached to a three-way stopcock) for vascular closure
Primary Outcome Measures
NameTimeMethod
Time to ambulation (TTA) after sheath removal1 day

Time to ambulation is defined as the elapsed time between removal of the final sheath and the moment when the patient can stand and walk 20 feet without evidence of venous re-bleeding from the femoral access site.

Secondary Outcome Measures
NameTimeMethod
Time to haemostasis1 day

time elapsed between removal of the vascular sheath and first observed and confirmed venous haemostasis, for each access site

Time to discharge eligibility1 day

time elapsed between removal of the final sheath and when the patient is eligible for hospital discharge based solely on the assessment of the access site, as determined by the medical team

Time to discharge1 day

time elapsed between removal of the final sheath and when the patient was discharged from the institution

Incidence of major periprocedural adverse events1 day

defined as adverse events until hospital discharge requiring medical intervention.

Incidence of major adverse events30 days

Major adverse events are defined as complications requiring medical intervention or hospitalisation

Incidence of minor adverse events30 days

Minor adverse events are defined as AEs not requiring medical intervention.

Comparison of EuroQol EQ-5D-5L30 days

Comparison of EuroQol 5-level EQ-5D score. The score is made up of two parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). The first part covers five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension offers five response options (no problems, slight problems, moderate problems, severe problems, and extreme problems), from which an EQ-5D index score is calculated, ranging from 0 (death) to 1 (perfect health). The EQ-VAS assesses an individual's self-perceived health for the day on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health), where participants mark their current health status.

Trial Locations

Locations (1)

The Essex Cardiothoracic Centre

🇬🇧

Basildon, Essex, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath